Adventrx Pharmaceuticals Inc., of San Diego, appointed Carrie Carlander chief financial officer and Brian Culley vice president of business development.
AEterna Zentaris Inc., of Quebec, appointed Gerard Limoges to its board. At its majority-owned subsidiary, Atrium Biotechnologies Inc., the company appointed Luc Dupont president, CEO and director; John Dempsey vice president and chief financial officer; Jocelyn Harvey vice president, mergers and acquisitions; Richard Bordeleau president of the health and nutrition division; Charles Boulanger president of active ingredients and specialty chemicals division; and Yvan Sergerie vice president of international sales and marketing in the health and nutrition division. Eric Dupont, Limoges and Jacques Gauthier will join Atrium's board, with Dupont serving as vice chairman.
Ascend Therapeutics, of Herndon, Va., appointed Alan Cutler director of pharmaceutical development.
Caliper Life Sciences Inc., of Hopkinton, Mass., appointed Thomas Higgins executive vice president and chief financial officer.
CV Therapeutics Inc., of Palo Alto, Calif., appointed Thomas Shenk to its board.
Cytogen Corp., of Princeton, N.J., appointed Michael Manyak vice president of medical affairs.
Exelixis Inc., of South San Francisco, appointed Alan Garber to its board.
Ganeden Biotech Inc., of Cleveland, appointed Mike Merriman, John Shields and Charles Strauss to its business advisory board.
The Institute for OneWorld Health, of San Francisco, appointed William Haseltine to its board.
Isis Pharmaceuticals Inc., of Carlsbad, Calif., appointed Richard DiMarchi to its board.
Izalex Inc., of Santa Barbara, Calif., appointed Tom Proulx to its board.
Memory Pharmaceuticals Corp., of Montvale, N.J., said Joseph Donabauer will oversee the company's finance function until a successor is named for Chief Financial Officer Dennis Keane, who is resigning. The company also appointed Robert Kriebel to its board and chairman of the audit committee.
Metaphore Pharmaceuticals Inc., of Fort Lee, N.J., appointed Harold Ingalls to its board.
Neurochem Inc., of Montreal, appointed Mariano Rodriguez vice president of finance and chief financial officer.
NPS Pharmaceuticals Inc., of Salt Lake City, appointed Michael Bonney and Rachel Selisker to its board.
Osiris Therapeutics, of Baltimore, appointed Cary Claiborne chief financial officer and Harry Carmitchel chief operating officer.
Oxis International Inc., of Portland, Ore., appointed Marvin Hausman to its board.